Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Loss of muscle mass arises from an imbalance of protein synthesis and protein degradation. Potential triggers of muscle wasting and function are immobilization, loss of appetite, dystrophies and chronic diseases as well as aging. All these conditions lead to increased morbidity and mortality in patients, which makes it a timely matter to find new biomarkers to get a fast clinical diagnosis and to develop new therapies. This mini-review covers current developments in the field of biomarkers and drugs on cachexia and sarcopenia. Here, we reported about promising markers, e.g. tartrate-resistant acid phosphatase 5a (TRACP5a), and novel substances like Epigallocatechin-3-gallate (EGCg). In summary, the progress to combat muscle wasting is in full swing and perhaps diagnosis of muscle atrophy and of course patient treatments could be soon supported by improved and more helpful strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989) · Science · doi:10.1126/science.2538923 · Cited by 1,535 · cited 1×
“Polyubiquinated proteins are subsequently degraded by the proteasome [16] while monoubiquitinated substrates are eliminated in lysosomes [17].”
BackgroundIKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.003 · Cited by 786 · cited 1×
“Loss ofmusclemass and function, especiallymuscle strength and gait speed, associated with aging occur in sarcopenia [6,7].”
BackgroundThe effectiveness of exercise interventions for the management of frailty: a systematic review
Theou, O., Stathokostas, L., Roland, K. P., Jakobi, J. M., Patterson, C., Vandervoort, A. A., & Jones, G. R. (2011) · Journal of Aging Research · doi:10.4061/2011/569194 · Cited by 652
Mitochondrial fission and remodelling contributes to muscle atrophy
Romanello, V., Guadagnin, E., Gomes, L., Roder, I., Sandri, C., Petersen, Y., Milan, G., Masiero, E., Del Piccolo, P., Foretz, M., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.60 · Cited by 596
Signaling pathways perturbing muscle mass.
Glass, D. J. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833862df · Cited by 359 · cited 2×
“factors (FoxO) in muscle [40] resulting in increased proteolysis by inducing the expression of MAFbx and MuRF-1 [15].”
BackgroundWasting in chronic kidney disease
Mak, R. H., Ikizler, A. T., Kovesdy, C. P., Raj, D. S., Stenvinkel, P., & Kalantar-Zadeh, K. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0019-5 · Cited by 281
Osteosarcopenic obesity: the role of bone, muscle, and fat on health
Ormsbee, M. J., Prado, C. M., Ilich, J. Z., Purcell, S., Siervo, M., Folsom, A., & Panton, L. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0146-x · Cited by 257
Cited by
Sarcopenia – Molecular mechanisms and open questions
Wiedmer, P., Jung, T., Castro, J. P., Pomatto, L. C. D., Sun, P. Y., Davies, K. J. A., & Grune, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101200 · Cited by 471
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
Self-citationChang, K.-V., Hsu, T.-H., Wu, W.-T., Huang, K.-C., & Han, D.-S. (2017) · Age and Ageing · doi:10.1093/ageing/afx094 · Cited by 276
Myricanol rescues dexamethasone-induced muscle dysfunction Via a sirtuin 1-dependent mechanism
Shen, S., Liao, Q., Liu, J., Pan, R., Lee, S. M., & Lin, L. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12393 · Cited by 142
Skeletal muscle wasting in chronic heart failure
Suzuki, T., Palus, S., & Springer, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12387 · Cited by 134
Self-citation
Metadata
- Authors
- Drescher, C., Konishi, M., Ebner, N., & Springer, J.
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 202
- Pages
- 766-772
- ISSN
- 0167-5273 (ISSN-L)
- OpenAlex
- W1963249349
- Cited by
- 53
- References
- 14
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment. https://app.cochat.ai/papers/10.1016/j.ijcard.2015.10.033
- The paper
- Drescher, C., Konishi, M., Ebner, N., & Springer, J. (2016). Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2015.10.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.